Ayrton Drugs Manufacturing Company Ltd. reported audited financial results for the nine months ended June 30, 2014. For the period, the company reported turnover of GHC 21,338,571 compared to GHC 24,077,076 a year ago. Operating loss was GHC 1,776,399 compared to operating profit of GHC 876,621 a year ago.

Loss before tax was GHC 1,846,653 compared to profit before tax of GHC 1,023,504 a year ago. Operating cash flow was negative at GHC 1,387,624 compared to operating cash flow of GHC 2,337,165 a year ago. Capital expenditures were GHC 971,693 compared to GHC 2,116,820 a year ago.

Basic and diluted loss per share was GHC 0.0074 compared to basic and diluted earnings per share of GHC 0.0016 a year ago. Net cash flows used in operating activities was GHC 1,387,625 compared to GHC 2,337,165 a year ago. Purchase of property, plant and equipment was GHC 957,813 compared to GHC 2,058,901 a year ago.

Purchase of intangible asset was GHC 13,880 compared to GHC 57,919 a year ago.